Aquilo Capital Management, LLC is 10% Owner at Spero Therapeutics, Inc. (SPRO). They have made 11 open-market trades across 2 companies since 2020, most recently 2022-09-22.
CIK 0001591986
8 open-market purchases totalling $13.3M since 2021, against 3 sales. Across 8 scored buys the stock is down 53.9% at ninety days, and 49.3 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 25% | 0% | 0% |
| Avg Move | -6.7% | -17.2% | -53.9% |
| Alpha | -4.4% | -14.1% | -49.3% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SPRO | SELL | 2022-09-22 | 2022-09-26 | $2.25 | $4.3M | -3.3% | -6.5% | -27.6% |
| SPRO | BUY | 2022-03-30 | 2022-03-31 | $8.79 | $879K | -7.9% | -27.2% | -88.5% |
| SPRO | BUY | 2022-02-18 | 2022-02-23 | $9.24 | $274K | -1.7% | -3.1% | -85.4% |
| SPRO | BUY | 2022-01-31 | 2022-02-01 | $11.59 | $1.4M | -11.6% | -21.0% | -55.2% |
| SPRO | BUY | 2022-01-18 | 2022-01-20 | $12.41 | $1.2M | -7.4% | -24.9% | -51.1% |
| SPRO | BUY | 2022-01-10 | 2022-01-12 | $12.93 | $229K | -6.4% | -19.1% | -48.1% |
| SPRO | BUY | 2021-12-29 | 2022-01-03 | $15.24 | $5.0M | -24.3% | -31.4% | -56.6% |
| SPRO | BUY | 2021-09-09 | 2021-09-10 | $18.50 | $916K | +3.8% | -7.0% | -24.2% |
| SPRO | BUY | 2021-08-30 | 2021-09-01 | $18.43 | $3.4M | +1.5% | -3.9% | -22.0% |
| SPRO | SELL | 2021-02-08 | 2021-02-10 | $21.74 | $130K | -10.5% | -20.0% | -37.9% |
| PIRS | SELL | 2020-07-21 | 2020-07-22 | $2.95 | $5.6M | -10.3% | +5.0% | -22.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.